Efficacy and Safety Analysis of Beliuzumab in the Treatment of Systemic Lupus Erythematosus
Objective To investigate the effect of beliuzumab in the treatment of systemic lupus erythematosus(SLE).Methods 60 SLE patients admitted to Jianhu County People's Hospital from January 2020 to December 2022 were selected as the research objects and were divided into a control group and an observation group according to random number table method,with 30 cases in each group.The control group was treated with prednisone combined with hydroxychloroquine sulfate,and the observation group was treated with beliuzumab on this basis.The therapeutic effects of the two groups were compared.Results The total effective rate of the observation group was 93.33%,higher than 70.00%of the control group,the difference was statistically significant(P＜0.05).The incidence of adverse reactions in the observation group was 10.00%,lower than 33.33%in the control group,and the difference was statistically significant(P＜0.05).After treatment,the levels of erythrocyte sedimentation rate,C-reactive protein,immunoglobulin G,24 hours urinary protein,anti-double-stranded DNA antibody,anti-nuclear antibody and anti-nucleosome antibody in the observation group were lower than those in the control group,and the levels of complement 3,complement 4 and platelet count were higher than those in the control group,the differences between the groups were statistically significant(P＜0.05).Conclusion The effect of beliuzumab in the treatment of SLE is ideal,which can improve the curative effect and effectively control the disease,and the adverse reactions after medication are less,which is worthy of clinical promotion.
NETL
NSTL
万方数据
